Adial Pharmaceuticals, Inc.

NasdaqCM:ADIL Stok Raporu

Piyasa değeri: US$6.5m

Adial Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Adial Pharmaceuticals's earnings have been declining at an average annual rate of -0.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Anahtar bilgiler

-0.2%

Kazanç büyüme oranı

28.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi6.0%
Gelir büyüme oranın/a
Özkaynak getirisi-285.0%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

Gelir ve Gider Dağılımı

Adial Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:ADIL Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-1252
31 Mar 240-1151
31 Dec 230-761
30 Sep 230-862
30 Jun 230-972
31 Mar 230-1082
31 Dec 220-1192
30 Sep 220-1494
30 Jun 220-1695
31 Mar 220-1797
31 Dec 210-1998
30 Sep 210-1798
30 Jun 210-1688
31 Mar 210-1377
31 Dec 200-1156
30 Sep 200-955
30 Jun 200-844
31 Mar 200-844
31 Dec 190-944
30 Sep 190-843
30 Jun 190-1442
31 Mar 190-1431
31 Dec 180-1220
30 Sep 180-1110
30 Jun 180-310
31 Mar 180-110
31 Dec 170-110
30 Sep 170-110
30 Jun 170-100
31 Mar 170000
31 Dec 160000

Kaliteli Kazançlar: ADIL is currently unprofitable.

Büyüyen Kar Marjı: ADIL is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ADIL is unprofitable, and losses have increased over the past 5 years at a rate of 0.2% per year.

Büyüme Hızlandırma: Unable to compare ADIL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ADIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Özkaynak Getirisi

Yüksek ROE: ADIL has a negative Return on Equity (-284.95%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin